DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS
  1. Home
  2. Research Programs
  3. Peer Review Alzheimer's
  4. Research Highlights/News
  5. 2024 Peer Reviewed Alzheimer's Research Program

NEWS RELEASE

Released: January 03, 2024

Department of Defense
Congressionally Directed Medical Research Programs (CDMRP)
Peer Reviewed Alzheimer's Research Program
Anticipated Funding Opportunities for Fiscal Year 2024 (FY24)

The FY24 Defense Appropriations Bill has not been signed into law. Although FY24 funds have not been appropriated for the Peer Reviewed Alzheimer’s Disease Research Program (PRARP), the PRARP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government.

The FY24 Defense Appropriations Act is anticipated to provide funding for the PRARP to support research that addresses the long-term implications of military service as they pertain to Alzheimer’s disease (AD) and related dementias (ADRD) for Service Members, Veterans, and the general public. The managing agent for the anticipated funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC).

The PRARP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY24 funding opportunities. This pre-announcement should not be construed as an obligation by the government. The FY24 PRARP funding opportunity announcements for the following award mechanisms will be posted on the Grants.gov website. Pre-application and application deadlines will be available when the announcements are released.

All FY24 PRARP mechanisms have a Career Initiation or Transition Partnering PI Option (CITPO) to encourage research capacity in this critical area. The CITPO investigator should have only nominal research support in the field and can be either a) a junior investigator three or more years from their terminal degree but no more than seven years into an independent position and/or b) transitioning from another field to the AD/ADRD/TBI field, and has only nominal, if any, publications in the AD-related field.
Award Mechanism Eligibility Key Mechanism Elements Funding
Transforming Care Award Any independent investigator at any career level.
  • Supports person-centered research that prioritizes the individual with AD/ADRD, their care partner/caregiver, and/or both and clearly demonstrates feasibility and identifies a realistic approach to scaling and implementation. “Care” does not refer to medical care (such as medical interventions administered by a physician).
  • Animal studies are not allowed.
  • Community collaboration is required.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Maximum funding of $1.4 million (M) for total costs.
  • CITPO: Maximum funding of $1.6M for total costs.
  • Maximum period of performance is 4 years. 
Transforming Diagnosis Award Any independent investigator at any career level.
  • Supports research to reduce barriers and improve diagnosis and prognosis of dementia of AD/ADRD following military service and/or TBI.
  • Community collaboration is required.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Maximum funding of $2.0M for total costs.
  • CITPO: Maximum funding of $2.0M for total costs.
  • Maximum period of performance is 4 years. 
Transforming Research Award Any independent investigator at any career level.
  • Supports high-impact research with high impact aimed to identify, validate, and/or mitigate risk factors which may contribute to dementia onset.
  • Clinical trials will not be supported, but studies with prospective human subjects’ enrollment may be allowed.
  • Clinical studies are required to have an element of community collaboration.
  • Submission of a Letter of Intent is required prior to full application submission.
  • Maximum funding of $1.0M for total costs.
  • CITPO: Maximum funding of $1.0M for total costs.
  • Maximum period of performance is 3 years. 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final funding opportunity announcement that will be available for downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Submission deadlines are not available until the funding opportunity announcements are released. For email notification when announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage. For more information about the PRARP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.health.mil).


Point of Contact:

CDMRP Public Affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@health.mil








Last updated Thursday, February 8, 2024